Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Paner · SciRah

Researcher profile · Semantic Scholar

A. Paner

Share profile

A. Paner — researcher profile on SciRah

h-index: 11
Works: 57
Citations: 553

Most-cited papers

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
P. Richardson, A. Oriol, A. Larocca, J. Bladé +21 more
2020Journal of Clinical Oncology113 citations Open access
Semantic Scholar
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma
E. Rowinsky, A. Paner, J. Berdeja, Claudia E. Paba-Prada +7 more
2020Investigational new drugs104 citations Open access
Semantic Scholar
The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma.
A. Paner, P. Patel, Binod Dhakal
2019Blood reviews44 citations
Semantic Scholar
Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study
R. Vij, M. Savona, D. Siegel, J. Kaufman +10 more
201431 citations
Semantic Scholar
Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study
A. Greenberg, S. Philip, A. Paner, S. Velinova +7 more
2015Blood Cancer Journal28 citations Open access
Semantic Scholar
Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study
A. Greenberg, S. Philip, A. Paner, S. Velinova +7 more
2015Blood Cancer Journal25 citations Open access
Semantic Scholar
Melflufen for relapsed and refractory multiple myeloma
A. Oriol, A. Larocca, X. Leleu, R. Hájek +6 more
2020Expert Opinion on Investigational Drugs20 citations Open access
Semantic Scholar
The Cardiologist and the Cancer Patient: Challenges to Cardio-Oncology (or Onco-Cardiology) and Call to Action.
T. Okwuosa, N. Prabhu, Hena Patel, T. Kuzel +3 more
2018Journal of the American College of Cardiology14 citations Open access
Semantic Scholar
Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study
A. Larocca, X. Leleu, C. Touzeau, J. Bladé +16 more
2021British Journal of Haematology13 citations Open access
Semantic Scholar
OP-106 Horizon — Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS
P. Richardson, E. Ocio, A. Oriol, A. Larocca +16 more
2018Blood12 citations
Semantic Scholar
Exercise, cancer and cardiovascular disease: what should clinicians advise?
A. Zimmerman, M. I. Planek, C. Chu, Opeyemi Oyenusi +5 more
2020Cardiovascular endocrinology & metabolism11 citations Open access
Semantic Scholar
HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis
P. Richardson, M. Mateos, A. Oriol, A. Larocca +19 more
2020Blood10 citations Open access
Semantic Scholar
Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab
M. Mateos, A. Oriol, A. Larocca, P. Rodríguez Otero +12 more
2019Blood9 citations Open access
Semantic Scholar
Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma
B. Derman, J. Reiser, S. Basu, A. Paner
2018International Journal of Nephrology9 citations Open access
Semantic Scholar
Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States
L. Gordan, A. Bensimon, Fan Mu, Nina Kim +12 more
2025Journal of Medical Economics8 citations Open access
Semantic Scholar
Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition
A. Masood, Trevor Christ, Samia Asif, P. Rajakumar +10 more
2021npj Genomic Medicine8 citations Open access
Semantic Scholar
When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds.
B. Gilmore, R. Rodby, D. Cimbaluk, P. Venugopal +9 more
2019Clinical Lymphoma, Myeloma & Leukemia8 citations
Semantic Scholar
Trends in the use of therapeutic plasma exchange in multiple myeloma
B. Dhakal, Sophie Miller, Lisa Rein, L. Pathak +10 more
2020Journal of clinical apheresis7 citations
Semantic Scholar
Triplet therapies – the new standard of care for multiple myeloma: how to manage common toxicities
A. Paner, T. Okwuosa, K. Richardson, E. Libby
2018Expert Review of Hematology7 citations
Semantic Scholar
Melphalan flufenamide for relapsed/refractory multiple myeloma.
O. Nadeem, M. Mateos, Y. Efebera, A. Paner +4 more
2022Drugs of Today6 citations
Semantic Scholar
Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study
K. Weisel, A. Paner, M. Engelhardt, F. Taylor +5 more
2018Blood6 citations Open access
Semantic Scholar
Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial
K. Weisel, M. Dimopoulos, J. San-Miguel, A. Paner +7 more
2021HemaSphere5 citations Open access
Semantic Scholar
HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents
Joan Batista Blade Creixenti, M. Mateos, A. Oriol, A. Larocca +18 more
20205 citations Open access
Semantic Scholar
HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).
M. Mateos, A. Oriol, A. Larocca, J. Bladé +16 more
20205 citations
Semantic Scholar
HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup Analysis
M. Mateos, A. Oriol, A. Larocca, Joan Batista Blade Creixenti +18 more
20205 citations Open access
Semantic Scholar
S1605 HORIZON (OP-106): UPDATED EFFICACY AND SAFETY OF MELFLUFEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO DARATUMUMAB (DARA) AND/OR POMALIDOMIDE (POM)
P. Richardson, A. Oriol, A. Larocca, P. R. Otero +16 more
2019HemaSphere5 citations Open access
Semantic Scholar
Cerebral Vein and Dural Venous Sinus Thrombosis: Risk Factors, Prognosis and Treatment—a Modern Approach
A. Paner, W. Jay, S. Nand, L. Michaelis
20095 citations
Semantic Scholar
Can Donor-Derived Cell-Free DNA Detect Graft-Versus-Host Disease in Solid Organ Transplantation: A Case Report.
Michael D. Williams, Joshua Thomas, A. Paner, E. Chan +5 more
2021Transplantation Proceedings4 citations
Semantic Scholar
Erratum: Racial differences in primary cytogenetic abnormalities in multiple myeloma: A multi-center study (Blood Cancer Journal (2015) 5 (e279) DOI: 10.1038/bcj.2015.8)
A. Greenberg, S. Philip, A. Paner, S. Velinova +7 more
20154 citations Open access
Semantic Scholar
HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety
P. Richardson, A. Oriol, A. Larocca, P. R. Otero +16 more
2019Clinical Lymphoma, Myeloma & Leukemia3 citations
Semantic Scholar
Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study
K. Weisel, A. Paner, M. Engelhardt, F. Taylor +4 more
2019Blood3 citations Open access
Semantic Scholar
The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone
P. Richardson, A. Larocca, X. Leleu, A. Oriol +12 more
2019Blood3 citations Open access
Semantic Scholar
Melflufen Therapy for Relapsed Refractory Multiple Myeloma (RRMM) Patients Refractory to Daratumumab and/or Pomalidomide: A Report on Early Efficacy
M. Mateos, J. Bladé, A. Larocca, A. Oriol +18 more
20173 citations
Semantic Scholar
HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Elderly Patients
A. Larocca, P. Richardson, A. Oriol, Joan Batista Blade Creixenti +18 more
20202 citations Open access
Semantic Scholar
Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population
P. Richardson, M. Mateos, P. Rodríguez-Otero, M. Norkin +12 more
2019Clinical Lymphoma, Myeloma & Leukemia2 citations
Semantic Scholar
Light Chain Amyloidosis Presenting as Bilateral External Auditory Canal Obstructing Masses.
Shenon Sethi, A. Paner, T. Okwuosa, Danny B. Jandali +3 more
2018Otology and Neurotology2 citations
Semantic Scholar
NEW-ONSET CARDIAC AMYLOIDOSIS WHILE IN REMISSION FROM SYSTEMIC AL AMYLOIDOSIS
A. Idowu, L. Tung, C. Chu, Jamario Skeete +2 more
2023European Journal of Case Reports in Internal Medicine1 citations Open access
Semantic Scholar
MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis
P. Richardson, M. Mateos, A. Oriol, A. Larocca +19 more
20211 citations
Semantic Scholar
The Impact of Non-Clinical Factors in Clinical Trial Enrollments of Patients with Hematologic Malignancies
J. Shammo, Anne Timmermann, D. Katz, A. Paner +7 more
2021Blood1 citations Open access
Semantic Scholar
Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.
P. Rodríguez-Otero, M. Mateos, A. Oriol, A. Larocca +16 more
20211 citations
Semantic Scholar
HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Health-Related Quality of Life (HRQoL) Analysis
A. Oriol, P. Richardson, M. Mateos, A. Larocca +20 more
20201 citations Open access
Semantic Scholar
HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy-Subgroup Analysis
P. Rodríguez-Otero, M. Mateos, A. Oriol, A. Larocca +18 more
20201 citations Open access
Semantic Scholar
P-441 Soluble urokinase plasminogen activator receptor (SuPAR) in patients with plasma cell dyscrasias, a pilot study
Y. Sudhini, Binod Dhakal, Jochen Reiser, Mehmet M. Altintas +4 more
2023Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
P-187: Retrospective review of chronic pain causes and management in multiple myeloma patients
A. Dave, Jamie Lewis, A. Paner
2022Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies
P. Rodríguez-Otero, M. Mateos, A. Oriol, A. Larocca +16 more
20210 citations
Semantic Scholar
A Unique Case of Leukocyte Chemotactic Factor 2 Pulmonary Amyloidosis Causing Acute Respiratory Distress Syndrome
A. Paruchuri, A. Paner, P. Rajakumar, M. Vash.i
2020TP34. TP034 INTERESTING DIFFUSE PARENCHYMAL LUNG DISEASE CASES0 citations
Semantic Scholar
MM-133: HORIZON (OP-106): Melflufen Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody (mAb) – Final Primary Analysis
P. Richardson, A. Oriol, A. Larocca, Joan Biadé +19 more
20200 citations
Semantic Scholar
Retrospective review of chronic pain causes and management in multiple myeloma patients.
A. Dave, Jaime K. Lewis, A. Paner
2020Journal of Clinical Oncology0 citations
Semantic Scholar
HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations
O. Nadeem, P. Richardson, M. Mateos, A. Oriol +19 more
20200 citations Open access
Semantic Scholar
Outcomes of COVID-19 Infection in Patients with Hematologic Malignancies
Elizabeth Behrens, Anne Timmermann, Alexander Yerkan, D. Katz +11 more
2020Blood0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Richardson×24
Invite
P. Richardson — researcher profile on SciRah
A. Larocca×23
Invite
A. Larocca — researcher profile on SciRah
M. Cavo×22
Invite
M. Cavo — researcher profile on SciRah
M. Mateos×22
Invite
M. Mateos — researcher profile on SciRah

×21

Invite

A. Oriol — researcher profile on SciRah

Invite

X. Leleu — researcher profile on SciRah

Christopher Maisel×21

Invite

Christopher Maisel — researcher profile on SciRah

Invite

H. Hassoun — researcher profile on SciRah

A. Mazumder×20

Invite

A. Mazumder — researcher profile on SciRah

J. Harmenberg×18

Invite

J. Harmenberg — researcher profile on SciRah

P. Rodríguez-Otero×16

Invite

P. Rodríguez-Otero — researcher profile on SciRah

Invite

C. Touzeau — researcher profile on SciRah